P2Y₁₂ inhibitors for acute coronary syndromes: current perspectives

References

• Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med. 2002;8(10):1175–1180.
   PubMed Web of Science ®Google Scholar
• Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J Intern Med. 2014;276(6):618–632.
   PubMed Web of Science ®Google Scholar
• Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):2354–2394.
   PubMed Web of Science ®Google Scholar
• O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362–e425.
   PubMed Web of Science ®Google Scholar
• Hamm CW, Bassand JP, Agewall S, et al; for the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2011;32(23):2999–3054.
   PubMed Web of Science ®Google Scholar
• Steg PG, James SK, Atar D, et al; for the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–2619.
   PubMed Web of Science ®Google Scholar
• ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988;2(8607):349–360.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, et al; for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.
   PubMed Web of Science ®Google Scholar
• The CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010; 363(10):930–942.
   Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, et al; for the CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179–1189.
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP, et al; for the COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet. 2005; 366(9497):1607–1621.
   PubMed Web of Science ®Google Scholar
• Mehta SR, Tanguay JF, Eikelboom JW, et al; on behalf of the CURRENT-OASIS 7 Investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376(9748):1233–1243.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease. The ONSET/OFFSET Study. Circulation. 2009;120(25):2577–2585.
   PubMed Web of Science ®Google Scholar
• Brilinta® (ticagrelor) tablets, for oral use [prescribing information]. Wilmington, DE: AstraZeneca LP; 2015.
   Google Scholar
• Effient® (prasugrel) tablets, for oral use [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2013.
   Google Scholar
• Plavix® (clopidogrel bisulfate) tablets [prescribing information]. Bridgewater, NJ: Bristol-Myers Squibb Sanofi Pharmaceuticals Partnership; 2013.
   Google Scholar
• Akers WS, Oh JJ, Oestreich JH, Ferraris S, Wethington M, Steinhubl SR. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol. 2010;50(1):27–35.
   PubMed Web of Science ®Google Scholar
• Greenbaum AB, Grines CL, Bittl JA, et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J. 2006;151(3):689.e1–689.e10.
   PubMed Web of Science ®Google Scholar
• Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients. RAPID (Rapid Activity of Platelet Inhibitor Drugs) Primary PCI Study. J Am Coll Cardiol. 2013;61(15):1601–1606.
   PubMed Web of Science ®Google Scholar
• Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50(19):1852–1856.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Trenk D, Frelinger AL, et al; for the PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation. 2007;116(25):2923–2932.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al; for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al; for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057.
   PubMed Web of Science ®Google Scholar
• Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361(124):2318–2329.
   Google Scholar
• Bhatt DL, Lincoff AM, Gibson CM, et al; CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361(124):2330–2341.
   Google Scholar
• Thygesen K, Alpert JS, White HD; on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J Am Coll Cardiol. 2007; 50(22):2173–2195.
   PubMed Web of Science ®Google Scholar
• White HD, Chew DP, Dauerman HL, et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J. 2012;163(2):182.e–190.e.
   Web of Science ®Google Scholar
• Bhatt DL, Stone GW, Mahaffey KW, et al; for the CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303–1313.
   PubMed Web of Science ®Google Scholar
• Lange RA, Hillis LD. The duel between dual antiplatelet therapies. N Engl J Med. 2013;368(14):1356–1357.
   PubMed Web of Science ®Google Scholar
• Kengreal™ (cangrelor) for injection, for intravenous use [prescribing information]. Parsippany, NJ: The Medicines Company; 2015.
   Google Scholar
• Angiolillo DJ, Firstenberg MS, Price MJ, et al; for the BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery. A randomized controlled trial. JAMA. 2012;307(3):265–274.
   PubMed Web of Science ®Google Scholar
• Schömig A, Neumann FJ, Walter H, et al. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol. 1997;29(1):28–34.
   Web of Science ®Google Scholar
• Leon MB, Baim DS, Popma JJ, et al; for the Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998;339(23):1665–1671.
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH; for the CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation. 2000;102(6):624–629.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Wiviott SD, Braunwald E, et al; for the TRITON-TIMI 38 Investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373(9665):723–731.
   PubMed Web of Science ®Google Scholar
• Steg PG, James S, Harrington RA, et al; for the PLATO Study Group. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention. A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010;122(21):2131–2141.
   PubMed Web of Science ®Google Scholar
• DiNicolantonio JJ, Serebruany VL. Exploring the reduction in myocardial infarctions in the PLATO trial: which patients benefited on ticagrelor vs clopidogrel? Int J Cardiol. 2013;165(3):396–397.
   Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ, et al; for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–533.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Harrington RA, James S, et al; for the PLATelet inhibition and patient Outcomes (PLATO) investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375(9711):283–293.
   PubMed Web of Science ®Google Scholar
• Lindholm D, Varenhorst C, Cannon CP, et al. Ticagrelor vs clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. 2014;35(31):2083–2093.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Ticagrelor for the Treatment of Acute Coronary Syndromes. NICE Technology Appraisal Guidance 236; 2011. Available from: https://www.nice.org.uk/guidance/ta236/resources/guidance-ticagrelor-for-the-treatment-of-acute-coronary-syndromes-pdf. Accessed May 19, 2015.
   Google Scholar
• James SK, Roe MT, Cannon CP, et al; PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011;342:d3527.
   PubMed Web of Science ®Google Scholar
• Roe MT, Armstrong PW, Fox KA, et al; for the TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297–1309.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Jakubowski JA, Ferreiro JL, et al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol. 2014;64(10):1005–1014.
   PubMed Web of Science ®Google Scholar
• Patti G, Proscia C, Di Sciascio G. Antiplatelet therapy in patients with diabetes mellitus and acute coronary syndrome. New insights from randomized trials. Circ J. 2014;78(1):33–41.
   Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd, et al; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. N Engl J Med. 2002;288(19):2411–2420.
   Google Scholar
• Wiviott SD, Braunwald E, Angiolillo DJ, et al; for the TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation. 2008;118(16):1626–1636.
   PubMed Web of Science ®Google Scholar
• James S, Angiolillo DJ, Cornel JH, et al; for the PLATO study group. Ticagrelor vs clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient outcomes (PLATO) trial. Eur Heart J. 2010;31(24):3006–3016.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M, et al; for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791–1800.
   PubMed Web of Science ®Google Scholar
• Tantcheva-Poór I, Zaigler M, Rietbrock S, Fuhr U. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics. 1999;9(2):131–144.
   PubMedGoogle Scholar
• Bliden KP, Dichiara J, Lawal L, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol. 2008;52(7):531–533.
   PubMed Web of Science ®Google Scholar
• Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109(25):3171–3175.
   PubMed Web of Science ®Google Scholar
• Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm. 2007;64:1917–1921.
   PubMed Web of Science ®Google Scholar
• Rollini F, Franchi F, Cho JR, et al. Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study. J Cardiovasc Transl Res. 2014;7(1):53–63.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Logan DK, et al. The Influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel. The PARADOX Study. J Am Coll Cardiol. 2013;62(6):505–512.
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Mega JL, et al. Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. Am Heart J. 2011;162(3):518.e–526.e.
   Web of Science ®Google Scholar
• Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MS. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol. 2009;53(15):1273–1278.
   PubMed Web of Science ®Google Scholar
• Berger JS, Bhatt DL, Steinhubl SR, et al. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation. 2009;120(23):2337–2344.
   PubMed Web of Science ®Google Scholar
• Sibbald M, Yan AT, Huang W, et al. Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the global registry of acute coronary events. Am Heart J. 2010;160(5):855–861.
   Web of Science ®Google Scholar
• Cornel JH, Ohman EM, Neely B; TRILOGY ACS Investigators. Impact of smoking status on platelet function and clinical outcomes with prasugrel vs clopidogrel in patients with acute coronary syndromes managed without revascularization: insights from the TRILOGY ACS trial. Am Heart J. 2014;168(1):76.e–87.e.
   Web of Science ®Google Scholar
• Cornel JH, Becker RC, Goodman SG, et al. Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes – insights from the PLATelet inhibition and patient outcomes (PLATO) trial. Am Heart J. 2012;164(3):334.e–342.e.
   Web of Science ®Google Scholar
• Bellemain-Appaix A, O’Connor SA, Silvain J, et al; for the ACTION group. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention. JAMA. 2012;308(23):2507–2517.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Bolognese L, Dudek D, et al; for the ACCOAST Investigators. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369(11):999–1010.
   PubMed Web of Science ®Google Scholar
• Montalescot G, van’t Hof AW, Lapostolle F, et al; for the ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371(11):1016–1027.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Steg PG. Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet. 2015;386(9990):292–302.
   Web of Science ®Google Scholar
• Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937–944.
   PubMed Web of Science ®Google Scholar
• Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol. 2008;52(12):1038–1039.
   PubMed Web of Science ®Google Scholar
• Evanchan J, Donnally MR, Binkley P, Mazzaferri E. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol. 2010;33(3):168–171.
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713–718.
   PubMed Web of Science ®Google Scholar
• Gaglia MA Jr, Torguson R, Hanna N, et al. Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes. Am J Cardiol. 2010;105(6):833–838.
   Web of Science ®Google Scholar
• Gupta E, Bansal D, Sotos J, Olden K. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci. 2010;55(7):1964–1968.
   PubMed Web of Science ®Google Scholar
• Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton pump inhibitors – a cohort study. Ann Intern Med. 2010;152(6):337–345.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989–997.
   PubMed Web of Science ®Google Scholar
• Zairis MN, Tsiaousis GZ, Patsourakos NG, et al. The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol. 2010;26(2):e54–e57.
   Web of Science ®Google Scholar
• Bhatt DL, Cryer BL, Contant CF, et al; for the COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–1917.
   PubMed Web of Science ®Google Scholar
• FDA. FDA Reminder to Avoid Concomitant Use of Plavix (Clopidogrel) and Omeprazole. Maryland: US Food and Drug Administration; 2010.
   Google Scholar
• FDA. Interaction between Esomeprazole/Omeprazole and Clopidogrel Label Change. Maryland: US Food and Drug Administration; 2015.
   Google Scholar
• Lundell L, Miettinen P, Myrvold HE, et al; Nordic GERD Study Group. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol. 2009;7(12):1292–1298.
   Web of Science ®Google Scholar
• Goodman SG, Clare R, Pieper KS, et al; Platelet Inhibition and Patient Outcomes Trial Investigators. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012;125(8):978–986.
   PubMed Web of Science ®Google Scholar
• Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010;153(6):378–386.
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Dormuth CR, Huang A, et al. Proton pump inhibitors and the risk of adverse cardiac events. PLoS One. 2013;8(12):e84890.
   Web of Science ®Google Scholar
• Shih CJ, Chen YT, Ou SM, Li SY, Chen TJ, Wang SJ. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardiol. 2014;177(1):292–297.
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Wojdyla DM, Carroll K, et al; on behalf of the PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2011;124(5):544–554.
   PubMed Web of Science ®Google Scholar
• Thomas MR, Storey RF. Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes. J Cardiovasc Transl Res. 2014;7(1):19–28.
   Web of Science ®Google Scholar
• Grzesk G, Kozinski M, Tantry US, et al. High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells. Biomed Res Int. 2013;2013:928271.
   PubMed Web of Science ®Google Scholar
• Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013;62(11):981–989.
   PubMed Web of Science ®Google Scholar
• Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009; 374(9706):1967–1974.
   PubMed Web of Science ®Google Scholar
• Dewilde WJM, Oirbans T, Verheugt FWA, for the WOEST study investigators, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomized, controlled trial. Lancet. 2013;381(9872):1107–1115.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199–e267.
   PubMed Web of Science ®Google Scholar
• You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy in atrial fibrillation. Chest. 2012;141(2 Suppl):e531S–e575S.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107(23):2908–2913.
   PubMed Web of Science ®Google Scholar
• Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45(8):1157–1164.
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45(2):246–251.
   PubMed Web of Science ®Google Scholar
• Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007;154(2):221–231.
   PubMed Web of Science ®Google Scholar
• Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets – definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost. 1999;82(3):1145–1152.
   PubMed Web of Science ®Google Scholar
• Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated metaanalysis. Thromb Haemost. 2010;103(4):841–848.
   PubMed Web of Science ®Google Scholar
• Aradi D, Komócsi A, Vorobcsuk A, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J. 2010; 160(3):543–551.
   PubMed Web of Science ®Google Scholar
• Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol. 2011;58(19):1945–1954.
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Abe T, Sato Y, Matsubara Y, Moriki T, Murata M. Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: a systematic review and meta-analysis. Platelets. 2013;24(5):352–361.
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS, et al; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097–1105.
   PubMed Web of Science ®Google Scholar
• Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial. Circulation. 2011;124(10):1132–1137.
   PubMed Web of Science ®Google Scholar
• Collet JP, Cuisset T, Rangé G, et al; ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367(22):2100–2109.
   PubMed Web of Science ®Google Scholar
• Trenk D, Stone GW, Gawaz M. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J Am Coll Cardiol. 2012;59(24):2159–2164.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Erlinge D, Ohman EM; TRILOGY ACS Platelet Function Substudy Investigators. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA. 2012;308(17):1785–1794.
   PubMed Web of Science ®Google Scholar
• Price MJ. Measured drug effect and cardiovascular outcomes in patients receiving platelet P2Y12 receptor antagonists. Clarifying the time and place for intensive inhibition. N Engl J Med. 2012;308(17):1806–1808.
   Google Scholar
• Aradi D, Storey RF, Komócsi A, et al; Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014;35(4):209–215.
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Trenk D, Schrör K, et al; EPA (European Platelet Academy). EPA (European Platelet Academy). Response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc Interv. 2013;6(11):1111–1128.
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R, et al; Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919–933.
   PubMed Web of Science ®Google Scholar
• Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost. 2007;5(8):1630–1636.
   PubMed Web of Science ®Google Scholar
• Blindt R, Stellbrink K, de Taeye A, et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost. 2007;98(6):1329–1334.
   PubMedGoogle Scholar
• Freynhofer MK, Brozovic I, Bruno V, et al. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein- phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events. Thromb Haemost. 2011;106(2):230–239.
   Web of Science ®Google Scholar
• Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2009;53(10):849–856.
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Weisz G, et al; ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382(9892):614–623.
   PubMed Web of Science ®Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303(8):754–762.
   PubMed Web of Science ®Google Scholar
• Campo G, Fileti L, de Cesare N, et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol. 2010;56(18):1447–1455.
   PubMed Web of Science ®Google Scholar
• Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol. 2011;57(25):2474–2483.
   PubMed Web of Science ®Google Scholar
• Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention a collaborative meta-analysis of individual participant data. J Am Coll Cardiol. 2011;58(19):1945–1954.
   PubMed Web of Science ®Google Scholar
• Chan NC, Eikelboom JW, Ginsberg JS, et al. Role of phenotypic and genetic testing in managing clopidogrel therapy. Blood. 2014;124(5):689–699.
   Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011; 124(23):e574–e651.
   PubMed Web of Science ®Google Scholar
• Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O’Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “Boxed Warning.” A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association. Circulation. 2010;122(5):537–557.
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution? J Thromb Haemost. 2012;10(3):327–336.
   PubMedGoogle Scholar
• Savi P, Nurden P, Nurden AT, Levy-Toledano S, Herbert JM. Clopidogrel: a review of its mechanism of action. Platelets. 1998; 9(3–4):251–255.
   PubMed Web of Science ®Google Scholar
• Sharma RK, Reddy HK, Singh VN, Sharma R, Voelker DJ, Bhatt G. Aspirin and clopidogrel hyporesponsiveness and non-responsiveness in patients with coronary artery stents. Vasc Health Risk Manag. 2009;5:965–972.
   PubMedGoogle Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009;119(19):2553–2560.
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354–362.
   PubMed Web of Science ®Google Scholar
• Wallentin L. P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J. 2009;30(16):1964–1977.
   PubMed Web of Science ®Google Scholar
• Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41(12):913–958.
   PubMed Web of Science ®Google Scholar
• Dandara C, Masimirembwa CM, Magimba A, et al. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur J Clin Pharmacol. 2001;57(1):11–17.
   PubMed Web of Science ®Google Scholar
• Myrand SP, Sekiguchi K, Man MZ, et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther. 2008;84(3):347–361.
   PubMed Web of Science ®Google Scholar
• FDA. FDA Drug Safety Communication: Reduced Effectiveness of Plavix (Clopidogrel) in Patients Who are Poor Metabolizers of the Drug. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm. Accessed May 19, 2015.
   Google Scholar
• Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol. 2010;56(2):134–143.
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet. 2001; 29(3):306–309.
   PubMed Web of Science ®Google Scholar
• Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821–1830.
   PubMed Web of Science ®Google Scholar
• Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J. 2011;11(3):199–206.
   PubMed Web of Science ®Google Scholar
• Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ. 2011;343:d4588.
   PubMed Web of Science ®Google Scholar
• Zabalza M, Subirana I, Sala J, et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart. 2012;98(2):100–108.
   PubMed Web of Science ®Google Scholar
• Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006;80(5):486–501.
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, et al; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–375.
   PubMed Web of Science ®Google Scholar
• Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos. 2007;35(5):1096–1104.
   Google Scholar
• Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos. 2006;34(4):600–607.
   PubMed Web of Science ®Google Scholar
• Riley AB, Tafreshi MJ, Haber SL. Prasugrel: a novel antiplatelet agent. Am J Health Syst Pharm. 2008;65(11):1019–1028.
   Web of Science ®Google Scholar
• Cuisset T, Loosveld M, Morange PE, et al. CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. JACC Cardiovasc Interv. 2012;5(12):1280–1287.
   PubMed Web of Science ®Google Scholar
• Sardella G, Calcagno S, Mancone M, et al. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel dose versus prasugrel. Circ Cardiovasc Interv. 2012;5(5):698–704.
   Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376(9749):1312–1319.
   PubMed Web of Science ®Google Scholar
• Kurihara A, Hagihara K, Kazui M, Ishizuka T, Farid NA, Ikeda T. In vitro metabolism of antiplatelet agent clopidogrel: cytochromeP450 isoforms responsible for two oxidation steps involved in the active metabolite formation. Drug Metab Rev. 2005;37(Suppl 2):99. [abstract].
   Google Scholar
• Alexopoulos D, Dimitropoulos G, Davlouros P, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel. The importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv. 2011;4(4):403–410.
   PubMed Web of Science ®Google Scholar
• de Labriolle A, Doazan JP, Lemesle G, Bonello L. Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists. Curr Cardiol Rep. 2011;13(5):439–450.
   Google Scholar
• Tantry US, Bliden KP, Wei C, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet. 2010;3(6):556–566.
   PubMed Web of Science ®Google Scholar
• Wallentin L, James S, Storey RF, et al; PLATO Investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010; 376(9749):1320–1328.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Trenk D, Frelinger AL, et al; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation- thrombolysis in myocardial infarction 44 trial. Circulation. 2007;116(25):2923–2932.
   PubMed Web of Science ®Google Scholar
• Lhermusier T, Lipinski MJ, Tantry US, et al. Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity. Am J Cardiol. 2015;115(6):716–723.
   PubMed Web of Science ®Google Scholar
• Aradi D, Tornyos A, Pintér T, et al. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing. Impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol. 2014;63(11):1061–1070.
   PubMed Web of Science ®Google Scholar
• Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet. 2012;379(9827):1705–1711.
   PubMed Web of Science ®Google Scholar
• Hulot JS, Fuster V. Antiplatelet therapy: personalized medicine for clopidogrel resistance? Nat Rev Cardiol. 2009;6(5):334–336.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation. 2012;125(10):1276–1287.
   PubMed Web of Science ®Google Scholar
• Liang ZY, Han YL, Zhang XL, Li Y, Yan CH, Kang J. The impact of gene polymorphisms and high on treatment platelet reactivity on clinical follow up: outcomes in patients with acute coronary syndrome after drug eluting stent implantation. EuroIntervention. 2013;9(3):316–327.
   Web of Science ®Google Scholar
• Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–858.
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol. 2010;55(22):2427–2434.
   PubMed Web of Science ®Google Scholar
• Bouman HJ, Harmsze AM, van Werkum JW, et al. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart. 2011;97(15):1239–1244.
   PubMed Web of Science ®Google Scholar
• Crespin DJ, Federspiel JJ, Biddle AK, Jonas DE, Rossi JS. Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis. Value Health. 2011;14(4):483–491.
   PubMed Web of Science ®Google Scholar
• Reese ES, Daniel Mullins C, Beitelshees AL, Onukwugha E. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy. 2012;32(4):323–332.
   PubMed Web of Science ®Google Scholar
• Kerneis M, Silvain J, Abtan J, et al. Switching acute coronary syndrome patients from prasugrel to clopidogrel. J Am Coll Cardiol Intv. 2013;6(2):158–165.
   Google Scholar
• Deharo P, Pons C, Pankert M, et al. Effectiveness of switching ‘hyper responders’ from Prasugrel to Clopidogrel after acute coronary syndrome: The POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study. Int J Cardiol. 2013;168(5):5004–5005.
   Web of Science ®Google Scholar